Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN ISSAC STONE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Endocrinology

NPI
1407172802
CMS profile
1342102
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$327.01

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $189.28 1
Food and Beverage $137.73 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie, Inc. $327.01 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN ISSAC STONE

NPI 1407172802 · CMS profile ID 1342102

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Endocrinology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407172802?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN ISSAC STONE, NPI 1407172802, CMS profile ID 1342102. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407172802?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STEPHEN ISSAC STONE, NPI 1407172802, CMS profile ID 1342102. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407172802?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STEPHEN ISSAC STONE, NPI 1407172802, CMS profile ID 1342102, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1407172802?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $327.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $105.0402/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647882335 CMS
AbbVie, Inc. $189.2801/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647882329 CMS
AbbVie, Inc. $32.6901/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647882331 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.01 3
PY2024 $22.36 1
PY2025 $49.26 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $227,321.82 120
PY2024 Principal investigator $63,847.68 22
PY2023 Principal investigator $63,002.04 18
PY2022 Principal investigator $23,087.03 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 12/12/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085228
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 12/12/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085230
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 12/12/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085232
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 12/12/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085234
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,003.28 12/05/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085200
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 12/05/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085202
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,003.28 12/05/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085204
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,009.84 12/05/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085206
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $35.55 12/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085190
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $88.50 12/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085192
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $41.00 12/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085194
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $45.69 12/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085196
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $45.69 12/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085198
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $46.56 11/06/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085236
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $24.92 11/06/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085238
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $300.00 11/06/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085240
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $680.00 10/08/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085222
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,224.00 10/08/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085224
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 10/08/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085226
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 10/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085208
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 10/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085210
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,738.64 10/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085212
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,094.00 10/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085214
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,395.92 10/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085216
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,160.64 10/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085218
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,395.92 10/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085220
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $24.60 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085170
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $12.30 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085172
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085174
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $540.04 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085176
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,080.08 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085178
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085180
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085182
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085184
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085186
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085188
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 09/10/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085154
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $20,032.80 09/10/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085156
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,003.28 09/10/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085158
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 07/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085146
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 07/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085148
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 07/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085150
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 07/01/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085152
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,738.64 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085046
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085048
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085050
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,738.64 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085052
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085054
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085056
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085058
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,094.00 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085060
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,094.00 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085062
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $450.00 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085064
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,540.00 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085066
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085068
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,003.28 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085070
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085072
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085074
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,009.84 06/25/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085076
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,009.84 06/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085080
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $8,013.12 06/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085082
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 06/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085084
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,009.84 06/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085086
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,003.28 06/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085088
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $8,013.12 06/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085090
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $24.92 06/09/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085166
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $240.00 06/09/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085168
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,006.56 06/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085078
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $28.95 06/03/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085034
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 06/03/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085036
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 06/03/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085038
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 06/03/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085040
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $70.80 06/03/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085042
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $32.80 06/03/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085044
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $24.60 05/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085144
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $35.55 04/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085130
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 04/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085132
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 04/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085134
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 04/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085136
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 04/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085138
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $82.71 04/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085140
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 04/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085142
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $75.00 03/24/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085028
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,500.00 03/21/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085012
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $220.00 03/10/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085092
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,395.92 03/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085008
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,689.68 03/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085010
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,395.92 03/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085016
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 03/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085020
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 03/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085022
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 03/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085024
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,094.00 03/07/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085026
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $49.20 03/03/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085128
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $37.38 02/27/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085164
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $46.56 02/21/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085160
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $360.00 02/21/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085162
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $141.60 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085112
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085114
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $60.92 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085116
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085118
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085120
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $82.71 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085122
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085124
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 02/04/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085126
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,094.00 01/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085002
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 01/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085004
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,094.00 01/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085006
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,998.80 01/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085014
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,738.64 01/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085018
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,523.76 01/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085030
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,689.68 01/13/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085032
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085094
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085096
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085098
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085100
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085102
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085104
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085106
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 01/02/2025 Non-covered Recipient Entity
Washington University
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085108
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $8.85 01/02/2025 Non-covered Recipient Entity
Washington University
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240085110